Transcript 100315_tuberculosis_theme_day_key_messages

World Tuberculosis Day 2010
Three key messages on
tuberculosis control
ECDC TB Team
European Centre for Disease Prevention and Control
Stockholm, 24 March 2010
Message 1
The treatment success rate in
the EU/EEA is too low to meet
global targets
1a. The treatment success rate in the
EU/EEA is too low to meet global targets
Reported treatment success rates in the EU/EEA are far below the
85% target set by the WHO World Health Assembly. Only three
EU/EEA countries recorded a treatment success rate over 85% or
more for new laboratory-confirmed pulmonary TB cases.
% Treatment success rate
Figure 1a: Treatment success rate among new laboratoryconfirmed pulmonary TB cases, 2007
85% target set
by the Stop TB
Partnership.
100
90
80
70
60
50
40
30
20
10
0
* Treatment success rate among not previously diagnosed cases.
Only Iceland,
Portugal and
Slovakia meet
the 85%
target.
Source: ECDC
1b. The treatment success rate in the
EU/EEA is too low to meet global targets
Figure 1b: Percentage success rate among laboratoryconfirmed new pulmonary TB cases, EU/EEA, 2007
< 60%
60 to 70%
71 to 84%
≥ 85%
Not
included or
not
reporting
Source: ECDC
1c. The treatment success rate in the
EU/EEA is too low to meet global targets
Treatment success among previously untreated laboratory-confirmed
pulmonary TB remains low in the EU/EEA and is below the 85% target.
No changes in the trend were seen in the last five years.
Figure 1c: EU/EEA treatment outcome among laboratoryconfirmed pulmonary cases 2003–2007
Previously untreated
Previously treated
All pulmonary cases
100.00
100
90.00
90
Transferred or
unknown
Still on treatment
Defaulted
80.00
80
Failed
70.00
70
Died
60.00
60
50.00
50
40.00
40
30
30.00
Success
20
20.00
10
10.00
0
0.00
2003 2004 2005 2006 2007
2003 2004 2005 2006 2007
2003 2004 2005 2006 2007
* Excluded: Austria, Bulgaria, Finland, France, Greece, Liechtenstein, Luxembourg, and Spain
* Excluded: Austria, Bulgaria, Cyprus, Finland, France, Greece, Italy, Liechtenstein and Spain
Message 2
Multidrug-resistant tuberculosis
(MDR TB) remains a problem in
the EU/EEA
2a. MDR TB* remains a problem in
the EU/EEA
Figure 2a: Proportion of notified TB cases with primary
multidrug resistance, EU/EEA, 2008
< 1%
1 to 1.9%
2 to 5.9%
> 6-10%
> 10%
Not included or
not reporting
* Multidrug-resistant tuberculosis (MDR TB) is defined as TB that is resistant at least to isoniazid (INH) and rifampicin (RMP),
the two most powerful first-line anti-TB drugs.
2b. MDR TB remains a problem in
the EU/EEA
Treatment success rate among MDR TB cases is extremely low (31%).
Figure 2b: Treatment outcome of all* MDR TB cases, compared
to all non-MDR cases, EU/EEA, 2006**
90
80
78%
70
60
50
40
31%
30
17%
17%
20
7%
10
6%
3%
17%
13%
2%
5%
5%
Non-MDR
MDR
0
Non-MDR
MDR
Non-MDR
Success
* Pulmonary and extra-pulmonary
MDR
Died
Non-MDR
MDR
Failed
Non-MDR
MDR
Defaulted
** Both groups are 2006 treatment cohorts
Non-MDR
MDR
Still on
treatment
Transferred
or unknown
Message 3
The decline in tuberculosis
has levelled off in the EU/EEA
3a. The decline in tuberculosis has
levelled off in the EU/EEA
The decline
seen in
countries with
high and
intermediate
incidence rates
contributes
substantially to
the average
EU/EEA
decline.
Source: ECDC
Figure 3a: TB notification rates by incidence grouping,
1995–2008 and 2002–2008
Notification rate (per 100 000 population)
The decrease
in TB
notification
rates has
stagnated in
the EU/EEA.
>20/100 000
EU/EEA
<20/100 000
3b. The decline in tuberculosis has
levelled off in the EU/EEA
Figure 3b: TB notification rates, 1995–2008, EU/EEA
25
25
20
20
15
15
10
10
5
5
0
0
2000 2002 2004 2006 2008
2001 2003 2005 2007
1995 1997 1999
1996 1998
Notification rate
(per 100 000
population)
19951996199719981999200020012002200320042005200620072008